Skip to content
Close
Customers
Biopharma
MedTech
Payers & Providers
Government
Products
Software Overview
Discover
Substantiate
Data Powered Offerings
Generate
Services
Regulatory & Scientific Services
Data Services
Company
About Us
Regulatory Partnerships
Leadership
Careers
Resources
News
Evidence Hub
Events
CARE Initiative
SEARCH
Let's Talk
Customers
Biopharma
MedTech
Payers & Providers
Government
Products
Software Overview
Discover
Substantiate
Data Powered Offerings
Generate
Services
Regulatory & Scientific Services
Data Services
Company
About Us
Regulatory Partnerships
Leadership
Careers
Resources
News
Evidence Hub
Events
CARE Initiative
Let's Talk
Quick results for "{search_term}"
Admin
Apr 12, 2021
< 1 min read
ICER to incorporate RWE into assessment of HAE drugs
Previous
Next
The US Institute for Clinical and Economic Review (ICER) has announced that it is using observational real-world evidence (RWE) to update its 2018 assessment of three therapies for long-term prophylaxis against hereditary angioedema (HAE) attacks.
Read More
Admin
RELATED ARTICLES
